Hematologist
CION Cancer Clinics
When MDS transforms into acute myeloid leukaemia | CION Cancer Clinics
MDS is usually called AML once immature blast cells make up 20% or more of the marrow or blood. Not everyone with MDS reaches that point, and the chance is much higher in higher-risk MDS. A bone marrow test confirms it. Treatment then depends on your fitness and gene results. This page explains the signs, the tests, the report words and the choices that follow. At CION Cancer Clinics, every leukaemia, MDS and MPN case is reviewed by our haematologist and discussed at a tumour board before a plan is agreed.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What does it mean when MDS turns into AML?
- What signs might suggest MDS is changing?
- How do doctors confirm the change to AML?
- What do the words on the marrow report mean?
- How is AML that came from MDS treated?
- What do families often believe about MDS turning into AML?
- Common questions about MDS transforming into AML
The short answer
What does it mean when MDS turns into AML?
It means the immature cells in the marrow, called blasts, have increased to the point where the illness now behaves like acute myeloid leukaemia (AML). Doctors usually call it AML once blasts make up 20% or more of the cells in the marrow or blood.
Why this can happen
MDS is a condition in which the marrow makes faulty blood cells. Over time, some people pick up further gene changes in those cells. A few of these changes let blasts grow faster and stop maturing. When that happens, the marrow fills with blasts and healthy cell production falls even further.
Does it happen to everyone?
No. Many people with MDS never develop AML. The chance is much higher in higher-risk MDS than in lower-risk MDS, which is one reason your risk score matters so much. Your haematologist can tell you where you sit, based on your own reports.
What this page cannot tell you
It cannot tell you whether your MDS will change, or when. It cannot give you an outlook. Those answers come from your marrow report, gene tests, general health and how you respond to treatment.
Blast percentages are read on marrow and blood samples, and laboratories report them in slightly different ways. One result is always read alongside earlier reports and symptoms.
!
Do not wait if these happen
If someone with MDS has a fever, shivering, bleeding that will not stop, blood in vomit or stool, sudden severe breathlessness or confusion, go to the nearest emergency department now or call 108. Say that the person has MDS and low blood counts. Do not wait for the next clinic visit, and do not give fever medicine first to see if it settles.
Not sure whether this applies to you?
Ask an oncologistWhat to watch
What signs might suggest MDS is changing?
None of these proves that AML has developed. Each one is a reason to contact your haematology team early rather than at the next routine visit.
Counts falling faster
Haemoglobin, platelets or white cells dropping more quickly than before, or transfusions suddenly needed more often.
More infections
Chest, urine or skin infections that come often, last longer or need stronger antibiotics than usual.
Bruising and bleeding
New bruises without injury, tiny red spots on the skin, or bleeding gums and nosebleeds that are hard to stop.
Changes on the blood report
Your report may mention blasts seen in the blood. This needs a doctor's review soon.
Other things people notice
- Much more tiredness than usual
- Bone aches
- Weight loss or night sweats
Getting a clear answer
How do doctors confirm the change to AML?
A full blood count and film
A blood count shows how far the numbers have moved. A specialist looks at the blood under a microscope to see whether blasts are present, and roughly how many.
A repeat bone marrow test
A small sample of marrow is taken from the hip bone. It shows the blast percentage accurately and is usually needed before any treatment decision is made.
Chromosome and gene tests
Tests on the marrow look for new chromosome or gene changes. These help decide which treatments may work, and whether a transplant is worth discussing.
A review of your fitness
Your heart, kidneys, liver and general strength are assessed, because they shape how intensive a treatment you can safely have.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
On your report
What do the words on the marrow report mean?
- Blasts
- Very young blood cells that have not matured. A small number is normal. A rising number is what separates MDS from AML.
- Secondary AML
- AML that has grown out of an earlier blood condition such as MDS, rather than appearing on its own.
- AML with myelodysplasia-related changes
- A report phrase meaning the leukaemia carries features that link it to MDS. It can affect treatment choices.
- MDS with increased blasts
- MDS in which blasts are raised but below the AML level. It is watched more closely.
- Cytogenetics
- Tests that look at the chromosomes in the marrow cells. The findings help predict how the illness may behave.
What comes next
How is AML that came from MDS treated?
Treatment depends mostly on your fitness, your gene results and what you want from treatment. The goal can be to control the leukaemia for as long as possible, or to keep you comfortable with good support.
Gentler treatment
Many people who develop AML after MDS are older or have other health problems. For them, azacitidine or a similar medicine, sometimes with venetoclax, is often discussed. These are usually given as day-care treatment rather than a long hospital stay.
Intensive chemotherapy and transplant
Fitter people may be offered intensive chemotherapy, which needs weeks in hospital. For some, a stem cell transplant is the only option with a chance of long-term control. Transplants are done at specialised centres. CION's haematology team can assess whether it is worth exploring and help coordinate the referral.
Who intensive treatment may not suit
People who are frail, have serious heart, kidney or lung problems, or would rather avoid long admissions are often better served by gentler treatment or supportive care. Choosing that path is a valid decision.
Questions worth asking your haematologist
Ask what the aim of each option is, and how you will know whether it is working. Ask how much time in hospital each path involves, what the likely side effects are, and what happens if the first treatment does not help. Ask whether a transplant is realistic for you, and if so, how soon a donor search should start. Write the answers down, or ask a family member to do it for you.
Commonly believed
What do families often believe about MDS turning into AML?
"MDS is a pre-cancer, so it always turns into leukaemia."
MDS is itself a type of blood cancer, and many people never develop AML. Lower-risk MDS in particular often stays stable for a long time with supportive care.
"The transfusions caused it to change."
Transfusions do not turn MDS into AML. The change comes from new faults in the marrow cells. Needing more blood is a sign that something has shifted, not the cause of it.
"If it has become AML, there is nothing more to do."
There are several options, from day-care medicines to intensive treatment and supportive care. Good symptom control is also real treatment. Ask your team what each path would involve.
"A normal blood count means the marrow is fine."
Blood counts are a useful guide, but blasts can rise in the marrow before the blood shows much change. That is why your team may ask for a repeat marrow test.
Questions we are asked
Common questions about MDS transforming into AML
How will I know if my MDS has turned into AML?
You usually cannot tell from symptoms alone. Falling counts, more infections or new bleeding raise the question, and a bone marrow test answers it. Your haematologist compares the blast count with earlier reports, since one result is read alongside symptoms and repeat tests.
Can treatment for MDS stop it becoming AML?
In higher-risk MDS, medicines such as azacitidine may delay the change for some people. A stem cell transplant, for those who are fit enough, is the treatment that can change the course most. No treatment can promise the change will never happen.
My report says blasts are rising but it is still MDS. What now?
This usually means closer follow-up and a fresh look at your risk score. Your team may repeat the marrow test sooner, and may discuss starting or changing treatment. Ask what the numbers mean for your plan, and when the next check will be.
Is AML after MDS harder to treat than other AML?
It often responds less well to standard chemotherapy, partly because of the gene changes it carries and partly because patients are often older. That is why treatment is planned carefully around each person. Your haematologist can explain what your own results suggest.
Does CION do stem cell transplants?
Transplants are carried out at specialised transplant centres. CION's haematology team evaluates your case, discusses it at a tumour board and helps coordinate assessment at a qualified centre. Ask about donor search, timing and cost early, since these take time to arrange.
Should brothers and sisters be tested as donors now?
Only if a transplant is being seriously considered. If your haematologist thinks it may be an option, testing siblings early can save weeks later. Ask the team whether it is worth starting, and where the testing should be done.
Can we choose not to have intensive treatment?
Yes. Many people choose gentler treatment or focus on comfort, and that choice deserves respect. Supportive care still includes transfusions, infection treatment and symptom control. Talk openly with your team about what matters most to the person who is ill.
What should we bring to the appointment?
Bring every marrow report, gene and chromosome results, recent blood counts, a list of medicines and a record of transfusions. Write down your questions first. Bring the family member who helps make decisions, so everyone hears the same explanation.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- National Cancer Institute — Myelodysplastic Syndromes Treatment (PDQ) - Patient Version
- American Cancer Society — Myelodysplastic Syndromes
- Leukemia & Lymphoma Society — Myelodysplastic Syndromes
- National Cancer Institute — Adult Acute Myeloid Leukemia Treatment (PDQ) - Patient Version
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Talk to us
Worried that MDS may be changing?
Share the latest blood counts and marrow reports. CION's haematology team will review them and explain the next step. One helpline serves every CION centre.